Video Insights
Advertisement
The first part of five segments from the live podcast, roundtable session on radioligands.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
The final segment of this roundtable series addresses the future of immunotherapy combinations.
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments.
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
In the fifth segment of this roundtable, the panelists discuss the challenges and barriers of ipi-nivo therapy.
The fourth segment of this roundtable series focuses on the potential benefits of subcutaneous nivolumab versus IV nivolumab.
The third segment of this roundtable focuses on key treatment endpoints when deciding between IO-IO and IO-TKI regimens.
The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA.
An expert panel debates the latest strategies for optimizing first-line treatment for advanced renal cell carcinoma.
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.